Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Takayasu Arteritis Clinical Presentation

  • Author: Jefferson R Roberts, MD; Chief Editor: Herbert S Diamond, MD  more...
 
Updated: Apr 13, 2016
 

History

The presentation of Takayasu arteritis is heterogeneous. Approximately 10% of patients with Takayasu arteritis are asymptomatic, and the diagnosis is suggested only by abnormal vascular findings on physical exam.[12, 17] Constitutional symptoms may precede clinical vascular involvement.

Constitutional symptoms include the following:[14, 12, 17, 18]

  • Headache (50-70%)
  • Malaise (35-65%)
  • Arthralgias (28-75%)
  • Fever (9-35%)
  • Weight loss (10-18%)

Cardiac and vascular features include the following:[14, 12, 17, 18, 19]

  • Bruit, with the most common location being the carotid artery (80%)
  • Blood pressure difference of extremities (45%-69%)
  • Claudication (38-81%)
  • Carotodynia or vessel tenderness (13-32%)
  • Hypertension (28-53%; 58% with renal artery stenosis in one series)
  • Aortic regurgitation (20-24%)
  • Raynaud’s syndrome (15%)
  • Pericarditis (<8%)
  • Congestive heart failure (<7%)
  • Myocardial infarction (<3%)

Neurologic features include the following:[14, 12, 17, 18, 19]

  • Headache (50-70%)
  • Visual disturbance (16-35%) - Strong association with common carotid and vertebral artery disease
  • Stroke (5-9%)
  • Transient ischemic attacks (3-7%)
  • Seizures (0-20%)

Dermatologic manifestations include the following:[12, 18, 19]

  • Erythema nodosum (6-19%)
  • Ulcerated subacute nodular lesions (<2.5%)
  • Pyoderma gangrenosum (<1%)

Classification criteria

The American College of Rheumatology has established classification criteria for Takayasu arteritis (3 of 6 criteria are necessary). The presence of any 3 or more criteria yields a sensitivity of 90.5% and a specificity of 97.8%.[20] The criteria are as follows:

  • Age of 40 years or younger at disease onset
  • Claudication of the extremities
  • Decreased pulsation of one or both brachial arteries
  • Difference of at least 10 mm Hg in systolic blood pressure between arms
  • Bruit over one or both subclavian arteries or the abdominal aorta
  • Arteriographic narrowing or occlusion of the entire aorta, its primary branches, or large arteries in the upper or lower extremities that is not due to arteriosclerosis, fibromuscular dysplasia, or other causes

Stages

Takayasu arteritis progresses through 3 stages. Thus, symptoms that clinicians encounter depend on how soon the patient presents; most patients present late, delaying the diagnosis. In actual practice, however, most patients do not fall readily into such groupings, and this 3-stage scheme is an oversimplification of the complex clinical presentation. Symptoms encountered can occur early or late in the course of the disease. In the aforementioned NIH series, which included 60 patients observed over 20 years, only 33% of patients had constitutional symptoms (corresponding to stage 1); 18% of patients never progressed to the third stage.

The first stage is an early systemic stage during which the patient may complain of constitutional symptoms (eg, fatigue, malaise, giddiness, fever). This stage is considered to be prevasculitic.

The second stage is the vascular inflammatory stage when stenosis, aneurysms, and vascular pain (carotidynia) tend to occur.

Signs and symptoms characterizing the vascular inflammatory stage include fatigue, fevers, malaise, pain in extremities and joints, dyspnea, palpitations, headaches, rash (erythema nodosum or a lupuslike butterfly rash, which can be photosensitive), hemoptysis, ulceration, and weight loss. A single case of thoracic and lumbar spine pain has been reported. Symptoms of vascular insufficiency include arm numbness, claudication in the legs (rare), blurry vision, double vision (which can be posture dependent), amaurosis fugax, stroke, transient ischemic attacks, hemiplegia, seizures, and paraplegia.

The constitutional systemic symptoms and vascular symptoms may occur at the same time, rendering the classification into stages practically impossible.

The third stage is the burned-out stage, when fibrosis sets in, and generally is associated with remission. This stage does not occur in all patients, and even in patients who are in remission, relapses can occur. Presumably, the burned-out stage manifests with minimal symptoms, but little supportive evidence is found in the literature.

Takayasu arteritis in pregnancy

Special mention should be made regarding pregnant women. The inflammatory activity is not enhanced by the pregnancy, but the perinatal period may be complicated by the associated symptoms. Blood pressure may not be measurable due to pulselessness, thus making patient monitoring difficult, if not impossible. Often, calf pressures need to be obtained.

In pregnant women with Takayasu arteritis, uncontrolled blood pressure may lead to subarachnoid/intracranial hemorrhage and subsequent seizures, eye changes, preeclampsia, aortic regurgitation, syncope, fetal complications, and nephrotic syndrome.

Next

Physical Examination

A thorough physical examination is essential, with particular attention paid to peripheral pulses, blood pressure in all 4 extremities, and ophthalmologic examination. The most discriminatory finding is a systolic blood pressure difference (>10 mm Hg) between arms.

Hypertension due to renal artery involvement (and sometimes leading to hypertensive encephalopathy) is found in approximately 50% of patients. Carotidynia may be present. Aortic regurgitation is a common finding.

Absent or diminished pulses are the clinical hallmark of Takayasu arteritis, but pulses are normal in many patients and upper limbs are affected more often than lower limbs. When pulselessness occurs, patient monitoring can be difficult or impossible, and often, calf blood pressures must be obtained.

Ophthalmologic examination may show retinal ischemia, retinal hemorrhages, cotton-wool exudates, venous dilatation and beading, microaneurysms of peripheral retina, optic atrophy, vitreous hemorrhage, and classic, wreathlike peripapillary arteriovenous anastomoses (extremely rare). Skin changes resembling erythema nodosum or ulcerating nodular lesions may be seen.

Other significant findings include the following:

  • Amaurosis fugax
  • Focal neurologic deficits consistent with cerebral infarction or transient ischemic attack
  • Vascular bruits, most commonly in the carotid and abdominal arteries but also in the subclavian and femoral arteries
  • Myocardial infarction
  • Dilated cardiomyopathy
  • Eclampsia
  • Subarachnoid hemorrhage, probably secondary to hypertension
  • Leg edema due to renal failure secondary to renal artery stenosis and glomerulonephritis

Less common associations have been seen with the following:

  • Ulcerative colitis
  • Sensorineural hearing loss
  • Pulmonary hemorrhage

A case report described sensorineural hearing loss associated with Takayasu arteritis.[21] Whether a firm connection between the 2 syndromes exists, other than the inflammatory manifestations, has not been demonstrated. The pathologic etiology of the hearing loss was attributed to an immune-mediated process in the membranous labyrinth.

Another case report described the presence of Cogan syndrome with Takayasu arteritis.[22] Cogan syndrome involves interstitial keratitis and a vestibuloauditory syndrome. Variations of this with other types of inflammatory eye disease and vestibuloauditory arteritis have also been reported.

Previous
 
 
Contributor Information and Disclosures
Author

Jefferson R Roberts, MD Chief of Rheumatology Service, Tripler Army Medical Center; Assistant Clinical Professor of Medicine, Uniformed Services University of the Health Sciences

Jefferson R Roberts, MD is a member of the following medical societies: American College of Physicians, American College of Rheumatology, Society for Simulation in Healthcare

Disclosure: Nothing to disclose.

Coauthor(s)

Rodger Stitt, MD Department of Internal Medicine, Tripler Army Medical Center, Honolulu

Rodger Stitt, MD is a member of the following medical societies: American College of Physicians

Disclosure: Nothing to disclose.

 

Disclosure: Nothing to disclose.

Phalgoon A Shah, MD Resident Physician, Department of Medicine, Tripler Army Medical Center

Phalgoon A Shah, MD is a member of the following medical societies: American College of Physicians

Disclosure: Nothing to disclose.

Chief Editor

Herbert S Diamond, MD Visiting Professor of Medicine, Division of Rheumatology, State University of New York Downstate Medical Center; Chairman Emeritus, Department of Internal Medicine, Western Pennsylvania Hospital

Herbert S Diamond, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, American College of Rheumatology, American Medical Association, Phi Beta Kappa

Disclosure: Nothing to disclose.

Additional Contributors

Gabriel Bucurescu, MD, MS Staff Neurologist, Neurology Service, Philadelphia Veterans Affairs Medical Center

Gabriel Bucurescu, MD, MS is a member of the following medical societies: American Academy of Neurology, American Clinical Neurophysiology Society, American Epilepsy Society

Disclosure: Nothing to disclose.

Robert E Wolf, MD, PhD Professor Emeritus, Department of Medicine, Louisiana State University School of Medicine in Shreveport; Chief, Rheumatology Section, Medical Service, Overton Brooks Veterans Affairs Medical Center

Robert E Wolf, MD, PhD is a member of the following medical societies: American College of Rheumatology, Arthritis Foundation, Society for Leukocyte Biology

Disclosure: Nothing to disclose.

Mohammed Mubashir Ahmed, MD Associate Professor, Department of Medicine, Division of Rheumatology, University of Toledo College of Medicine

Mohammed Mubashir Ahmed, MD is a member of the following medical societies: American College of Physicians, American College of Rheumatology, American Federation for Medical Research

Disclosure: Nothing to disclose.

Acknowledgements

Elliot Goldberg, MD Dean of the Western Pennsylvania Clinical Campus, Professor, Department of Medicine, Temple University School of Medicine

Elliot Goldberg, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, and American College of Rheumatology

Disclosure: Nothing to disclose.

B Mark Keegan, MD, FRCPC Assistant Professor of Neurology, College of Medicine, Mayo Clinic; Master's Faculty, Mayo Graduate School; Consultant, Department of Neurology, Mayo Clinic, Rochester

B Mark Keegan, MD, FRCPC is a member of the following medical societies: American Academy of Neurology, American Medical Association, and Minnesota Medical Association

Disclosure: Novartis Consulting fee Consulting

Sydney Louis, MBBCh, MD Emeritus Professor, Department of Neurology, The Warren Alpert Medical School of Brown University

Sydney Louis, MBBCh, MD is a member of the following medical societies: American Academy of Neurology

Disclosure: Nothing to disclose.

Michael G Rossman, MD, LTC, MC, FS Fellow, Department of Rheumatology, Walter Reed Army Medical Center

Michael G Rossman, MD, LTC, MC, FS is a member of the following medical societies: American College of Physicians, American College of Rheumatology, American Medical Association, and Society of US Army Flight Surgeons

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Senior Pharmacy Editor, eMedicine

Disclosure: eMedicine Salary Employment

Florian P Thomas, MD, MA, PhD, Drmed Director, Spinal Cord Injury Unit, St Louis Veterans Affairs Medical Center; Director, National MS Society Multiple Sclerosis Center; Director, Neuropathy Association Center of Excellence, Professor, Department of Neurology and Psychiatry, Associate Professor, Institute for Molecular Virology, and Department of Molecular Microbiology and Immunology, St Louis University School of Medicine

Florian P Thomas, MD, MA, PhD, Drmed is a member of the following medical societies: American Academy of Neurology, American Neurological Association, American Paraplegia Society, Consortium of Multiple Sclerosis Centers, and National Multiple Sclerosis Society

Disclosure: Nothing to disclose.

References
  1. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994 Feb. 37(2):187-92. [Medline].

  2. Hata A, Noda M, Moriwaki R, Numano F. Angiographic findings of Takayasu arteritis: new classification. Int J Cardiol. 1996 Aug. 54 Suppl:S155-63. [Medline].

  3. Arnaud L, Haroche J, Mathian A, Gorochov G, Amoura Z. Pathogenesis of Takayasu's arteritis: a 2011 update. Autoimmun Rev. 2011 Nov. 11(1):61-7. [Medline].

  4. Aggarwal A, Chag M, Sinha N, Naik S. Takayasu's arteritis: role of Mycobacterium tuberculosis and its 65 kDa heat shock protein. Int J Cardiol. 1996 Jul 5. 55(1):49-55. [Medline].

  5. Kumar Chauhan S, Kumar Tripathy N, Sinha N, Singh M, Nityanand S. Cellular and humoral immune responses to mycobacterial heat shock protein-65 and its human homologue in Takayasu's arteritis. Clin Exp Immunol. 2004 Dec. 138(3):547-53. [Medline]. [Full Text].

  6. Soto ME, Vargas-Alarcón G, Cicero-Sabido R, Ramírez E, Alvarez-León E, Reyes PA. Comparison distribution of HLA-B alleles in mexican patients with takayasu arteritis and tuberculosis. Hum Immunol. 2007 May. 68(5):449-53. [Medline].

  7. Yagi K, Kobayashi J, Yasue S, Yamaguchi M, Shiobara S, Mabuchi H. Four unrelated cases with Takayasu arteritis and CD36 deficiency: possible link between these disorders. J Intern Med. 2004 Jun. 255(6):688-9. [Medline].

  8. Hall S, Barr W, Lie JT, Stanson AW, Kazmier FJ, Hunder GG. Takayasu arteritis. A study of 32 North American patients. Medicine (Baltimore). 1985 Mar. 64(2):89-99. [Medline].

  9. Numano F, Kobayashi Y. Takayasu arteritis--beyond pulselessness. Intern Med. 1999 Mar. 38(3):226-32. [Medline].

  10. Jain S, Kumari S, Ganguly NK, Sharma BK. Current status of Takayasu arteritis in India. Int J Cardiol. 1996 Aug. 54 Suppl:S111-6. [Medline].

  11. Phillip R, Luqmani R. Mortality in systemic vasculitis: a systematic review. Clin Exp Rheumatol. 2008 Sep-Oct. 26(5 Suppl 51):S94-104. [Medline].

  12. Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, Rottem M, et al. Takayasu arteritis. Ann Intern Med. 1994 Jun 1. 120(11):919-29. [Medline].

  13. Maksimowicz-McKinnon K, Clark TM, Hoffman GS. Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. Arthritis Rheum. 2007 Mar. 56(3):1000-9. [Medline].

  14. Park MC, Lee SW, Park YB, Chung NS, Lee SK. Clinical characteristics and outcomes of Takayasu's arteritis: analysis of 108 patients using standardized criteria for diagnosis, activity assessment, and angiographic classification. Scand J Rheumatol. 2005 Jul-Aug. 34(4):284-92. [Medline].

  15. Abularrage CJ, Slidell MB, Sidawy AN, Kreishman P, Amdur RL, Arora S. Quality of life of patients with Takayasu's arteritis. J Vasc Surg. 2008 Jan. 47(1):131-6; discussion 136-7. [Medline].

  16. Akar S, Can G, Binicier O, Aksu K, Akinci B, Solmaz D, et al. Quality of life in patients with Takayasu's arteritis is impaired and comparable with rheumatoid arthritis and ankylosing spondylitis patients. Clin Rheumatol. 2008 Jul. 27(7):859-65. [Medline].

  17. Maksimowicz-McKinnon K, Clark TM, Hoffman GS. Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. Arthritis Rheum. 2007 Mar. 56(3):1000-9. [Medline].

  18. Soto ME, Espinola N, Flores-Suarez LF, Reyes PA. Takayasu arteritis: clinical features in 110 Mexican Mestizo patients and cardiovascular impact on survival and prognosis. Clin Exp Rheumatol. 2008 May-Jun. 26(3 Suppl 49):S9-15. [Medline].

  19. Francès C, Boisnic S, Blétry O, Dallot A, Thomas D, Kieffer E. Cutaneous manifestations of Takayasu arteritis. A retrospective study of 80 cases. Dermatologica. 1990. 181(4):266-72. [Medline].

  20. Arend WP, Michel BA, Bloch DA, Hunder GG, Calabrese LH, Edworthy SM, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum. 1990 Aug. 33(8):1129-34. [Medline].

  21. Siglock TJ, Brookler KH. Sensorineural hearing loss associated with Takayasu's disease. Laryngoscope. 1987 Jul. 97(7 Pt 1):797-800. [Medline].

  22. Raza K, Karokis D, Kitas GD. Cogan's syndrome with Takayasu's arteritis. Br J Rheumatol. 1998 Apr. 37(4):369-72. [Medline].

  23. Miller DV, Maleszewski JJ. The pathology of large-vessel vasculitides. Clin Exp Rheumatol. 2011 Jan-Feb. 29(1 Suppl 64):S92-8. [Medline].

  24. Gilden D, White TM, Nagae L, Gurdin WH, Boyer PJ, Nagel MA. Successful Antiviral Treatment of Giant Cell Arteritis and Takayasu Arteritis. JAMA Neurol. 2015 Aug. 72 (8):943-6. [Medline].

  25. Katz-Agranov N, Tanay A, Bachar DJ, Zandman-Goddard G. What to do when the Diagnosis of Giant Cell Arteritis and Takayasu's Arteritis Overlap. Isr Med Assoc J. 2015 Feb. 17 (2):123-5. [Medline]. [Full Text].

  26. Tripathy NK, Chandran V, Garg NK, Sinha N, Nityanand S. Soluble endothelial cell adhesion molecules and their relationship to disease activity in Takayasu's arteritis. J Rheumatol. 2008 Sep. 35 (9):1842-5. [Medline].

  27. Schmidt WA, Blockmans D. Use of ultrasonography and positron emission tomography in the diagnosis and assessment of large-vessel vasculitis. Curr Opin Rheumatol. 2005 Jan. 17(1):9-15. [Medline].

  28. Andrews J, Mason JC. Takayasu's arteritis--recent advances in imaging offer promise. Rheumatology (Oxford). 2007 Jan. 46(1):6-15. [Medline].

  29. Andrews J, Al-Nahhas A, Pennell DJ, Hossain MS, Davies KA, Haskard DO, et al. Non-invasive imaging in the diagnosis and management of Takayasu's arteritis. Ann Rheum Dis. 2004 Aug. 63(8):995-1000. [Medline]. [Full Text].

  30. Dagna L, Salvo F, Tiraboschi M, et al. Pentraxin-3 as a marker of disease activity in takayasu arteritis. Ann Intern Med. 2011 Oct 4. 155(7):425-33. [Medline].

  31. Direskeneli H, Aydin SZ, Merkel PA. Assessment of disease activity and progression in Takayasu's arteritis. Clin Exp Rheumatol. 2011 Jan-Feb. 29(1 Suppl 64):S86-91. [Medline].

  32. Magnani L, Versari A, Salvo D, et al. [Disease activity assessment in large vessel vasculitis]. Reumatismo. 2011. 63(2):86-90. [Medline].

  33. Blockmans D. PET in vasculitis. Ann N Y Acad Sci. 2011 Jun. 1228:64-70. [Medline].

  34. Fujita T, Ohtsuka M, Uchida E, Yamaguchi H, Nakajima T, Akazawa H, et al. Takayasu arteritis evaluated by multi-slice computed tomography in an old man. Int J Cardiol. 2008 Apr 10. 125(2):286-7. [Medline].

  35. Ragab Y, Emad Y, El-Marakbi A, Gheita T. Clinical utility of magnetic resonance angiography (MRA) in the diagnosis and treatment of Takayasu's arteritis. Clin Rheumatol. 2007 Aug. 26(8):1393-5. [Medline].

  36. Salvarani C, Magnani L, Catanoso M, et al. Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatology (Oxford). 2012 Jan. 51(1):151-6. [Medline].

  37. Unizony S, Stone JH, Stone JR. New treatment strategies in large-vessel vasculitis. Curr Opin Rheumatol. 2013 Jan. 25(1):3-9. [Medline].

  38. Yokoe I, Haraoka H, Harashima H. A patient with Takayasu's arteritis and rheumatoid arthritis who responded to tacrolimus hydrate. Intern Med. 2007. 46(22):1873-7. [Medline].

  39. Maksimowicz-McKinnon K, Hoffman GS. Takayasu arteritis: what is the long-term prognosis?. Rheum Dis Clin North Am. 2007 Nov. 33(4):777-86, vi. [Medline].

  40. Hoffman GS, Merkel PA, Brasington RD, et al. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum. 2004 Jul. 50(7):2296-304. [Medline].

  41. Youngstein T, Peters JE, Hamdulay SS, Mewar D, Price-Forbes A, Lloyd M, et al. Serial analysis of clinical and imaging indices reveals prolonged efficacy of TNF-a and IL-6 receptor targeted therapies in refractory Takayasu arteritis. Clin Exp Rheumatol. 2014 May-Jun. 32(3 Suppl 82):S11-8. [Medline].

  42. Tanaka F, Kawakami A, Iwanaga N, Tamai M, Izumi Y, Aratake K, et al. Infliximab is effective for Takayasu arteritis refractory to glucocorticoid and methotrexate. Intern Med. 2006. 45(5):313-6. [Medline].

 
Previous
Next
 
Complete occlusion of the left common carotid artery in a 48-year-old woman with Takayasu disease. Also note narrowing of the origin of the right subclavian artery and a narrowed small vessel with subsequent aneurysmal dilatation on the right side. Image courtesy of Robert Cirillo, MD.
Characteristic long, tapered narrowing of the distal aorta and iliac vessels. Image courtesy of Robert Cirillo, MD.
Image obtained in the same patient as in Image 2 reveals narrowing of the proximal descending aorta and right brachiocephalic artery. Image courtesy of Robert Cirillo, MD.
Aortogram of a 15-year-old girl with Takayasu arteritis. Note large aneurysms of descending aorta and dilatation of innominate artery. Image courtesy of Christine Hom, MD.
MRI of thorax of 15-year-old girl with Takayasu arteritis. Note aneurysms of descending aorta. Image courtesy of Christine Hom, MD.
Coronal MRI of abdomen of 15-year-old girl with Takayasu arteritis. Note thickening and tortuosity of abdominal aorta proximal to kidneys. Image courtesy of Christine Hom, MD.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.